Table 5.
Reference | No of participants* | Clinical background | Duration of trial (years) | No of events | Adjusted risk ratio for venous thromboembolism (95% CI) | |
---|---|---|---|---|---|---|
Hormone replacement therapy group | Placebo group | |||||
PEPI 1995w12 | 847 | “Healthy” | 3 | 4 | 0† | 1.9 (0.1 to 36.5)‡§ |
HERS 1998w13 | 2763 | History of coronary heart disease | 4.1 | 34 | 12 | 2.9 (1.5 to 5.6) |
EVTET 2000w14 | 140 | History of venous thromboembolism | 1.3 | 8 | 1 | 7.8 (1.0 to 60.5) |
ERA 2000w15 | 309 | History of coronary heart disease | 3.2 | 7 | 1¶ | 3.6 (0.5 to 28.9)‡ |
WEST 2001w16 | 664 | History of stroke | 2.8 | 3 | 4 | 0.8 (0.2 to 3.4) |
ESPRIT 2002w17 | 1017 | History of coronary heart disease | 2 | 5 | 4 | 1.2 (0.3 to 4.6) |
WHI I 2002w18 | 16608 | “Healthy” | 5.2 | 151 | 67 | 2.1 (1.6 to 2.7) |
WHI II 2004w19 | 10739 | “Healthy” | 7 | 77 | 54 | 1.3 (1.0 to 1.8) |
WISDOM 2007w20 | 5692 | Possible history of arterial disease | 0.99 | 22 | 3 | 7.4 (2.2 to 24.6) |
*About equal number in placebo and active treatment group except for two trials.w12 w15
†Hormone replacement therapy group n=682; placebo group n=165.
‡Risk calculated from data reported in study.
§To estimate risk ratio, number of events in placebo group was considered equal to 0.5.
¶Hormone replacement therapy group n=204; placebo group n=105.